Lilly’s big Jaypirca test approaches
After failure of its second-line trial to show an OS benefit, the pressure is on in the front line.
AACR 2025 preview – new preclincal approaches abound
Novel targets including Ly6E and LRRC15 feature alongside more popular mechanisms.
Acrivon CHKs itself
The company is abandoning ovarian and bladder, but still sees a path in endometrial cancer.
Pfizer dials down its atirmociclib ambitions
The company is stepping back in second-line breast cancer.
